Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 3/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15559495 | 0.81 | ALDH1A1 (0.39) | KMT2AMEN1GSK3AGSK3BMAT2A | |
| SCHEMBL15598612 | 0.78 | KDM4E (0.39) | KMT2AMEN1GSK3AGSK3BMAT2A | |
| SCHEMBL15598613 | 0.76 | GSK3B (0.34) | KMT2AGSK3AGSK3BMAT2APDE11A | |
| SCHEMBL15598610 | 0.76 | GSK3B (0.34) | KMT2AGSK3AGSK3BMAT2APDE11A | |
| SCHEMBL15550320 | 0.76 | GSK3B (0.34) | KMT2AGSK3AGSK3BMAT2APDE11A | |
| SCHEMBL15558529 | 0.76 | COMT (0.36) | KMT2AMEN1GSK3AGSK3BMAT2A | |
| SCHEMBL15559028 | 0.71 | GSK3A (0.30) | GSK3AGSK3BPDE11A | |
| SCHEMBL17986919 | 0.68 | PIK3CD (0.31) | GSK3B | |
| SCHEMBL7986168 | 0.65 | DYRK1B (0.41) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL18372281 | 0.65 | MEN1 (0.37) | KMT2AMEN1ATMMAT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017214269-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016119707-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-08-04 | — | — | WO | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| EP-2877472-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF | Hutchison Medipharma Limited (CN) | 2015-06-03 | — | — | EP | disclosed |
| EP-2861588-A2 | NOVEL THERAPEUTICS FOR BRAIN CANCER | The Regents of The University of California (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014015523-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015675-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015675-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015830-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015830-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015523-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013188813-A2 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | KMT2A 3819/4885MEN1 1386/4885ATM 626/4885 |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KMT2A 3819/4885MEN1 1386/4885ATM 626/4885 |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KMT2A 3819/4885MEN1 1386/4885ATM 626/4885 |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | PIK3C2B, PIK3C3, PIK3C2A | KMT2A 2912/4885MEN1 1364/4885ATM 1787/4885 |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | KMT2A 3911/4885MEN1 2006/4885ATM 741/4885 |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KMT2A 3819/4885MEN1 1386/4885ATM 626/4885 |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | KMT2A 3671/4885MEN1 1188/4885ATM 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.